283 related articles for article (PubMed ID: 10548672)
1. Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke.
Chalela JA; Kasner SE; Jauch EC; Pancioli AM
Stroke; 1999 Nov; 30(11):2366-8. PubMed ID: 10548672
[TBL] [Abstract][Full Text] [Related]
2. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
Weintraub MI
Stroke; 2006 Jul; 37(7):1917-22. PubMed ID: 16728683
[TBL] [Abstract][Full Text] [Related]
3. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany.
Audebert HJ; Kukla C; Vatankhah B; Gotzler B; Schenkel J; Hofer S; Fürst A; Haberl RL
Stroke; 2006 Jul; 37(7):1822-7. PubMed ID: 16763192
[TBL] [Abstract][Full Text] [Related]
4. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
[TBL] [Abstract][Full Text] [Related]
5. Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants--Case Series and Systematic Review of Reported Cases.
Shahjouei S; Tsivgoulis G; Bavarsad Shahripour R; Jones GM; Alexandrov AV; Zand R
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2685-93. PubMed ID: 26542821
[TBL] [Abstract][Full Text] [Related]
6. Safety of protocol violations in acute stroke tPA administration.
Lyerly MJ; Albright KC; Boehme AK; Bavarsad Shahripour R; Houston JT; Rawal PV; Kapoor N; Alvi M; Sisson A; Alexandrov AW; Alexandrov AV
J Stroke Cerebrovasc Dis; 2014; 23(5):855-60. PubMed ID: 23954609
[TBL] [Abstract][Full Text] [Related]
7. Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke.
Martin-Schild S; Hallevi H; Albright KC; Khaja AM; Barreto AD; Gonzales NR; Grotta JC; Savitz SI
Arch Neurol; 2008 Sep; 65(9):1174-8. PubMed ID: 18779419
[TBL] [Abstract][Full Text] [Related]
8. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
[TBL] [Abstract][Full Text] [Related]
9. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
[TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.
Graham GD
Stroke; 2003 Dec; 34(12):2847-50. PubMed ID: 14605319
[TBL] [Abstract][Full Text] [Related]
11. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV
Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774
[TBL] [Abstract][Full Text] [Related]
12. Role of tissue plasminogen activator in acute ischemic stroke.
Hatcher MA; Starr JA
Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
[TBL] [Abstract][Full Text] [Related]
13. Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.
Adelman EE; Scott PA; Skolarus LE; Fox AK; Frederiksen SM; Meurer WJ
J Stroke Cerebrovasc Dis; 2016 Jan; 25(1):67-73. PubMed ID: 26419527
[TBL] [Abstract][Full Text] [Related]
14. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older : the tPA stroke survey experience.
Tanne D; Gorman MJ; Bates VE; Kasner SE; Scott P; Verro P; Binder JR; Dayno JM; Schultz LR; Levine SR
Stroke; 2000 Feb; 31(2):370-5. PubMed ID: 10657408
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
[TBL] [Abstract][Full Text] [Related]
16. The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature.
Edwards NJ; Kamel H; Josephson SA
Stroke; 2012 Feb; 43(2):412-6. PubMed ID: 22156701
[TBL] [Abstract][Full Text] [Related]
17. Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe?
Martin-Schild S; Morales MM; Khaja AM; Barreto AD; Hallevi H; Abraham A; Sline MR; Jones E; Grotta JC; Savitz SI
J Emerg Med; 2011 Aug; 41(2):135-41. PubMed ID: 19272734
[TBL] [Abstract][Full Text] [Related]
18. Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011.
Lubeck DP; Danese MD; Duryea J; Halperin M; Tayama D; Yu E; Lalla D; Grotta JC
Int J Stroke; 2016 Feb; 11(2):198-205. PubMed ID: 26783311
[TBL] [Abstract][Full Text] [Related]
19. Protocol adherence and safety of intravenous thrombolysis after telephone consultation with a stroke center.
Uchino K; Massaro L; Jovin TG; Hammer MD; Wechsler LR
J Stroke Cerebrovasc Dis; 2010; 19(6):417-23. PubMed ID: 21051004
[TBL] [Abstract][Full Text] [Related]
20. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
